While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.
Profits are valuable, but they’re not everything. At StockStory, we help you identify the companies that have real staying power. Keeping that in mind, here is one profitable company that generates reliable profits without sacrificing growth and two best left off your watchlist.
Two Stocks to Sell:
Somnigroup (SGI)
Trailing 12-Month GAAP Operating Margin: 12.1%
Established through the merger of Tempur-Pedic and Sealy in 2012, Somnigroup (NYSE: SGI) is a bedding manufacturer known for its innovative memory foam mattresses and sleep products
Why Is SGI Risky?
- Muted 14.5% annual revenue growth over the last five years shows its demand lagged behind its consumer discretionary peers
- Free cash flow margin is not anticipated to grow over the next year
- Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned
Somnigroup’s stock price of $72.50 implies a valuation ratio of 22x forward P/E. Read our free research report to see why you should think twice about including SGI in your portfolio.
Gibraltar (ROCK)
Trailing 12-Month GAAP Operating Margin: 10.5%
Gibraltar (NASDAQ: ROCK) makes renewable energy, agriculture technology and infrastructure products. Its mission statement is to make everyday living more sustainable.
Why Should You Sell ROCK?
- Annual sales declines of 3.1% for the past two years show its products and services struggled to connect with the market during this cycle
- Earnings per share have contracted by 9.1% annually over the last two years, a headwind for returns as stock prices often echo long-term EPS performance
- 7× net-debt-to-EBITDA ratio shows it’s overleveraged and increases the probability of shareholder dilution if things turn unexpectedly
At $40.31 per share, Gibraltar trades at 0.9x trailing 12-month price-to-sales. To fully understand why you should be careful with ROCK, check out our full research report (it’s free).
One Stock to Watch:
Medpace (MEDP)
Trailing 12-Month GAAP Operating Margin: 21%
Founded in 1992 as a scientifically-driven alternative to traditional contract research organizations, Medpace (NASDAQ: MEDP) provides outsourced clinical trial management and research services to help pharmaceutical, biotechnology, and medical device companies develop new treatments.
Why Is MEDP on Our Radar?
- Core business can prosper without any help from acquisitions as its organic revenue growth averaged 16.9% over the past two years
- Performance over the past five years was turbocharged by share buybacks, which enabled its earnings per share to grow faster than its revenue
- Free cash flow margin grew by 8.3 percentage points over the last five years, giving the company more chips to play with
Medpace is trading at $467.41 per share, or 27.2x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
